|
gptkbp:instanceOf
|
gptkb:drug
statin
|
|
gptkbp:approvalYear
|
2003
2009
|
|
gptkbp:approvedBy
|
gptkb:Japan
gptkb:United_States
|
|
gptkbp:ATCCode
|
gptkb:C10AA08
|
|
gptkbp:brand
|
gptkb:Livazo
gptkb:Livalo
Zypitamag
|
|
gptkbp:CASNumber
|
147511-69-1
|
|
gptkbp:chemicalFormula
|
pyrimidine-based statin
|
|
gptkbp:contraindication
|
pregnancy
lactation
active liver disease
|
|
gptkbp:developedBy
|
gptkb:Kowa_Pharmaceuticals
|
|
gptkbp:drugClass
|
statin
|
|
gptkbp:eliminationHalfLife
|
11 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C50H46CaF2N2O8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pitavastatin calcium
|
|
gptkbp:IUPACName
|
calcium (3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Japan
|
|
gptkbp:mechanismOfAction
|
HMG-CoA reductase inhibitor
|
|
gptkbp:metabolism
|
liver (CYP2C9, CYP2C8)
|
|
gptkbp:molecularWeight
|
880.98 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:proteinBinding
|
>99%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
myalgia
rhabdomyolysis
liver enzyme elevation
|
|
gptkbp:synonym
|
gptkb:Livazo
gptkb:Livalo
|
|
gptkbp:usedFor
|
gptkb:familial_hypercholesterolemia
dyslipidemia
|
|
gptkbp:bfsParent
|
gptkb:Pitavastatin
|
|
gptkbp:bfsLayer
|
8
|